A recent study reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end conventional diet and exercise programs.
Findings released in a leading health publication demonstrates that while obese individuals often shed substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of nearly a kilo each month once they quit.
"People purchasing such treatments must be cognizant of the risk of rapid rebound weight gain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
That rate of regain implies a return to original mass in about 18 months.
Weighing Approaches
The analysis, which examined dozens of trials involving thousands of patients, compared the results of the injectable medications with other pills.
Researchers note that individuals who lose weight through lifestyle changes alone generally have a slower creep back—around 100 grams monthly—post-intervention.
Understanding the Rapid Regain
Doctors propose the way of the jabs explains the accelerated regain.
These medications imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 levels far above than normal could lead to the body to produce less of its own natural hormone, and may also reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating far more likely."
A Chronic Disease?
The NHS advise the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the treatment should be considered ongoing.
This view is reinforced by pharmaceutical companies, who note that the results "highlight the chronic nature of excess weight," similar to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the medication explain a intense return of hunger.
"I experienced a trigger activating and I was suddenly starving," recalled an individual.
The struggle is compounded if users have not developed sustainable lifestyle or habit changes during treatment.
Significant Interest
Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with demand remaining high.
- Use is higher among women than men.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, researchers stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone solution and lasting health benefits hinges on integrated behavioural support.
